SUCRALOSE
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 398.0 | -1.7 | 5 | 8 | 129.0 | 5 | 1.0 |
- CAS
- 56038132
- UNII
- 96K6UQ3ZD4
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 2 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT01200940 | 2010-06-01 | Metabolic Effects of Non-Nutritive Sweeteners | Phase 1/Phase 2 | Recruiting |
(Browse) Purchasable Analogs in ZINC
Functions of Sucralose
| Nns - Non-nutritive sweetener |
Regulatory Status of Sucralose
| Reg - Food additives for which a petition has been filed and a regulation issued. |
Dosages
| Route | Formulation | Per Unit Dose |
|---|---|---|
| Buccal | Gum, Chewing | 2MG |
| Nasal | Solution, Spray | 0.15% |
| Nasal | Spray | 0.15% |
| Nasal | Spray, Metered | 0.15%W/V |
| Oral | Film, Soluble | 5.5MG |
| Oral | Granule | 5.4MG |
| Oral | Granule, For Oral Suspension | 2.33MG |
| Oral | Powder, For Oral Solution | 1210MG |
| Oral | Powder, For Oral Suspension | 9% |
| Oral | Solution | 0.6%W/W |
| Oral | Suspension | 1.1% |
| Oral | Tablet | 4.67MG |
| Oral | Tablet (immed./comp. Release), Uncoated, Chewable | 1.88MG |
| Oral | Tablet, Effervescent, For Solution | 4MG |
| Oral | Tablet, Orally Disintegrating | 5.75MG |
| Oral | Tablet, Uncoated, Lozenge | 0.76MG |
| Oral | Troche | 4MG |
| Oral-28 | Tablet | 0.02MG |
| Sublingual | Tablet | 1.3MG |
| Sublingual | Tablet (immed./comp. Release), Uncoated, Buccal | 0.52MG |
| Sublingual | Tablet, Uncoated, Lozenge | 1.5MG |